ROIV Stock Recent News

Roivant Sciences' shares are up more than 42% over the past year. The company recently released a report on a phase 3 trial of its atopic dermatitis treatment.

Roivant Sciences Limited saw its shares rise after its subsidiary Dermavant Sciences reported positive topline results from ADORING 2, one of two Phase 3 studies to evaluate the effectiveness and safety of topical VTAMA (tapinarof) cream. The Long Beach, California-based biopharma said both adult and pediatric atopic dermatitis (AD) subjects received the VTAMA cream, and 1% received the same dose and dose regimen as the cream is already approved for in adults with plaque psoriasis.

Shares of Roivant Sciences Ltd. ROIV gained about 6% in trading on Wednesday after the company said its experimental atopic dermatitis treatment met the primary endpoint in a Phase 3 clinical trial.

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q3 2022 Earnings Conference Call February 13, 2023 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matthew Gline - CEO Frank Torti - MD, Vant Chair Mayukh Sukhatme - President & Chief Investment Officer Conference Call Participants Brian Cheng - JP Morgan Louise Chen - Cantor Neena Bitritto-Garg - Citi Robyn Karnauskas - Truist Corinne Jenkins - Goldman Sachs Dennis Ding - Jefferies Douglas Tsao - HCW Operator Good day, and thank you for standing by.

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -36.11% and 19.31%, respectively, for the quarter ended December 2022.

Roivant's differentiated approach to the drug development business has been hit and miss. The company's subsidiary Dermavant won a first approval this year for Vtama cream - indicated for plaque psoriasis.

Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Jeffrey Kalmus - Head, Strategic Finance Matt Gline - CEO Conference Call Participants David Risinger - SVB Securities Brian Cheng - J.P.

Roivant Sciences Ltd. (ROIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Roivant Sciences Ltd. (ROIV) was a big mover last session on higher-than-average trading volume.